6,11-Dioxobenzo[]pyrido[1,2-]indoles Kill by Targeting Iron-Sulfur Protein Rv0338c (IspQ), A Putative Redox Sensor.

ACS infectious diseases, Volume: 6, Issue: 11
November 13, 2020
Rita Székely R, Monica Rengifo-Gonzalez M, Vinayak Singh V, Olga Riabova O, Andrej Benjak A, Jérémie Piton J, Mena Cimino M, Etienne Kornobis E, Valerie Mizrahi V, Kai Johnsson K, Giulia Manina G, Vadim Makarov V, Stewart T Cole ST

Screening of a diversity-oriented compound library led to the identification of two 6,11-dioxobenzo[]pyrido[1,2-]indoles (DBPI) that displayed low micromolar bactericidal activity against the Erdman strain of . The activity of these hit compounds was limited to tubercle bacilli, including the nonreplicating form, and to . On hit expansion and investigation of the structure activity relationship, selected modifications to the dioxo moiety of the DBPI scaffold were either neutral or led to reduction or abolition of antimycobacterial activity. To find the target, DBPI-resistant mutants of Erdman were raised and characterized first microbiologically and then by whole genome sequencing. Four different mutations, all affecting highly conserved residues, were uncovered in the essential gene () that encodes a membrane-bound protein, named IspQ, with 2Fe-2S and 4Fe-4S centers and putative iron-sulfur-binding reductase activity. With the help of a structural model, two of the mutations were localized close to the 2Fe-2S domain in IspQ and another in transmembrane segment 3. The mutant genes were recessive to the wild type in complementation experiments and further confirmation of the hit-target relationship was obtained using a conditional knockdown mutant of in H37Rv. More mechanistic insight was obtained from transcriptome analysis, following exposure of to two different DBPI; this revealed strong upregulation of the redox-sensitive SigK regulon and genes induced by oxidative and thiol-stress. The findings of this investigation pharmacologically validate a novel target in tubercle bacilli and open a new vista for tuberculosis drug discovery.

Courtesy of the U.S. National Library of Medicine